Vactosertib

Generic Name: Vactosertib

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₂₂H_₁₈FN_₇

CAS Number: 1352608-82-2

Unique Ingredient Identifier: 6T4O391P5Y

Background: Vactosertib is under investigation in clinical trial NCT03724851 (Vactosertib in Combination With Pembrolizumab in Metastatic Colorectal or Gastric Cancer).

Associated Conditions: -

Associated Therapies: -

Clinical Trials

Vactosertib and Imatinib Combination in Patients with Advanced Desmoid Tumor/aggressive Fibromatosis (DT/AF)

Phase 2

Withdrawn

Conditions: Dermoid

Interventions: Drug: Vactosertib
Drug: Imatinib

First Posted Date: 2024-01-23

Last Posted Date: 2024-12-09

Lead Sponsor: MedPacto, Inc.

Target Recruit Count: 76

Registration Number: NCT06219733

Locations: 🇰🇷
Yeonsei University Severance Hospital, Seoul, Korea, Republic of

Oral TGF-beta Receptor I Inhibitor Vactosertib in SOC Chemoradiotherapy for Esophageal Adenocarcinoma

Phase 2

Recruiting

Conditions: Adenocarcinoma Esophagus
Locally Advanced Adenocarcinoma
Siewert Type II Adenocarcinoma of Esophagogastric Junction
Siewert Type I Adenocarcinoma of Esophagogastric Junction

Interventions: Drug: Vactosertib
Drug: Standard of Care Chemotherapy
Radiation: Concurrent Radiation

First Posted Date: 2023-09-21

Last Posted Date: 2024-11-28

Lead Sponsor: Jennifer Eva Selfridge, MD

Target Recruit Count: 25

Registration Number: NCT06044311

Locations: 🇺🇸
University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States

Study to Assess Safety and Efficacy of Vactosertib in Adolescents and Adults With Recurrent, Refractory or Progressive Osteosarcoma

Phase 1

Recruiting

Conditions: Osteosarcoma

Interventions: Drug: Vactosertib

First Posted Date: 2022-10-20

Last Posted Date: 2024-05-02

Lead Sponsor: MedPacto, Inc.

Target Recruit Count: 48

Registration Number: NCT05588648

Locations: 🇺🇸
Washington University - St. Louis, Saint Louis, Missouri, United States
🇺🇸
UH Rainbow Babies & Children's Hospital, Cleveland, Ohio, United States
🇰🇷
National Cancer Center, Gyeonggi-do, Korea, Republic of

and more 3 locations

Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer

Phase 1

Recruiting

Conditions: Colorectal Cancer
Hematologic Malignancy
Rectum Cancer
Acute Myeloid Leukemia
Myelodysplastic Syndromes
Acute Lymphoblastic Leukemia
Chronic Myeloid Leukemia
Chronic Lymphocytic Leukemia
Hodgkin Lymphoma
Non Hodgkin Lymphoma

Interventions: Drug: Vactosertib
Drug: Fludarabine Phosphate
Drug: Cyclophosphamide
Drug: IL-2
Drug: Natural Killer Cells

First Posted Date: 2022-06-01

Last Posted Date: 2024-11-29

Lead Sponsor: Jennifer Eva Selfridge, MD

Target Recruit Count: 12

Registration Number: NCT05400122

Locations: 🇺🇸
University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States

As a Second-line Treatment for Metastatic Gastric Adenocarcinoma Patients, the Safety and Effective of Vactosertib Administration in Combination With Paclitaxel+Ramucirumab is Evaluated, and a Phase 2a Clinical Trial to Biomarkers

Phase 2

Not yet recruiting

Conditions: Gastric Cancer

Interventions: Drug: Vactosertib

First Posted Date: 2020-12-07

Last Posted Date: 2022-06-15

Lead Sponsor: Samsung Medical Center

Target Recruit Count: 43

Registration Number: NCT04656002

Vactosertib With Nal-IRI/FL in Metastatic Pancreatic Ductal Adenocarcinoma.

Phase 1

Conditions: Pancreas Cancer

Interventions: Drug: Vactosertib

First Posted Date: 2020-02-06

Last Posted Date: 2022-06-15

Lead Sponsor: Samsung Medical Center

Target Recruit Count: 24

Registration Number: NCT04258072

Locations: 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of

Intra-patient Dose Escalation Study to Investigate Safety and Feasibility of Vactosertib in Treating Anemic MPN Patients

Phase 2

Terminated

Conditions: Myeloproliferative Neoplasm

Interventions: Drug: Vactosertib

First Posted Date: 2019-09-25

Last Posted Date: 2024-11-11

Lead Sponsor: Weill Medical College of Cornell University

Target Recruit Count: 2

Registration Number: NCT04103645

Locations: 🇺🇸
Weill Medical College of Cornell University, New York, New York, United States

Preoperative Immunotherapy (Pembrolizumab) for Patients With Colorectal Cancer and Resectable Hepatic Metastases

Phase 2

Recruiting

Conditions: Stage IVA Colorectal Cancer AJCC v8
Stage IVC Colorectal Cancer AJCC v8
Stage IVB Colorectal Cancer AJCC v8
Metastatic Malignant Neoplasm in the Liver
Stage IV Colorectal Cancer AJCC v8

Interventions: Procedure: Hepatectomy
Biological: Pembrolizumab
Drug: Vactosertib

First Posted Date: 2019-02-18

Last Posted Date: 2023-10-11

Lead Sponsor: Chloe Atreya, MD, PhD

Target Recruit Count: 19

Registration Number: NCT03844750

Locations: 🇺🇸
University of California, San Francisco, San Francisco, California, United States

Vactosertib in Combination w/ Pomalidomide in Relapsed or Relapsed and Refractory Multiple Myeloma

Phase 1

Completed

Conditions: Multiple Myeloma

Interventions: Drug: Vactosertib
Drug: Pomalidomide

First Posted Date: 2017-05-08

Last Posted Date: 2024-05-24

Lead Sponsor: Koen van Besien

Target Recruit Count: 18

Registration Number: NCT03143985

Locations: 🇺🇸
University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States

Prev
1
Next

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy